Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR

By: via Benzinga
Celladon Corporation (Nasdaq: CLDN), a clinical-stage biotechnology company developing novel therapies for patients with heart failure ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.